iBio Inc, IBIO Securities Lawsuit
Lucy Campbell, 16 December 2014
Los Angeles, CA: A securities class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased iBio, Inc. (“iBio” or the “Company”) (NYSE MKT:IBIO) securities between October 13, 2014 and October 23, 2014.
The Complaint alleges that during the Class Period, the Company issued materially false and misleading statements to investors by wrongfully suggesting that the Company’s Launch platform patents and related proprietary technology would be licensed by the makers of the experimental Ebola drug, ZMapp. The Complaint alleges that when the true facts were revealed, the price of the Company’s stock fell significantly, damaging investors.
Continue reading “Article: iBio Inc, IBIO Securities Lawsuit”
IBIO – don’t buy the vaccine dream
mariner_admin, 08 December 2020
IBIO is a Texas-based company whose stock was up ~500% year to date through 12/7 on investor optimism about its COVID-19 vaccine efforts. We believe that IBIO is vaccine vaporware, with a history of having inserted itself into the discourse of several diseases-du-jour over the last decade including H1N1, Ebola, and now COVID. IBIO has never actually commercialized any of its vaccine or therapeutics efforts, having eliminated pipeline disclosure in FY17.
In fact, IBIO settled a shareholder suit alleging that it lied about its Ebola claims, and we believe IBIO’s COVID effort is just a replay of the 2014 Ebola episode. Despite this, the Roberts (Kay and Erwin), have reaped compensation in excess of 100% of IBIO’s revenues since 2008
Continue reading “Article: IBIO – don’t buy the vaccine dream”
Another great study is ticker IBIO https://www.ibioinc.com/ with everything going on today with COVID-19.
iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health, including a virus-like particle (VLP) -based vaccine against SARS-CoV-2. iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing.
The Rosen Law Firm Announces Investigation of Securities Fraud Claims Against iBio, Inc. – IBIO
Business Wire, 24 October 2014
The Rosen Law Firm, P.A. announces that it is investigating potential securities fraud claims against iBio, Inc. (NYSE: IBIO).
On October 9, 2014, the Washington Post reported that the manufacturer of the experimental Ebola drug ZMapp was seeking additional production capacity from Caliber Biotherapeutics (“Caliber”). On October 16, 2014, iBio issued a press release titled “iBio Responds to Inquiries About its Role in Emergency Response to Ebola Virus Disease Outbreak”, which (among other things) “confirmed  the applicability of its issued U.S. iBio Launch platform patents and related proprietary technology to further development and production of antibodies that target the Ebola virus” and that it had been working with Caliber. iBio further “offered to assist the U.S. government by making its proprietary technology available [to] address the current Ebola virus outbreak”.
Continue reading “Article: The Rosen Law Firm Announces Investigation of Securities Fraud Claims Against iBio, Inc. – IBIO”